VIARTRIL PD.ORA.SOL 1,884(1,5)G/SACHET Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

viartril pd.ora.sol 1,884(1,5)g/sachet

meda pharmaceuticals s.a., greece Αγίου Δημητρίου 63, 17456 Αλιμος 210.6775690 - glucosamine sulfate - pd.ora.sol (ΚΟΝΙΣ ΓΙΑ ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 1,884(1,5)g/sachet - glucosamine sulfate 1.500mg - glucosamine

VIARTRIL F.C.TAB 750MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

viartril f.c.tab 750mg/tab

meda pharmaceuticals s.a., greece Αγίου Δημητρίου 63, 17456 Αλιμος 210.6775690 - glucosamine sulfate sodium salt - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 750mg/tab - glucosamine sulfate sodium salt 942mg - glucosamine

Pirfenidone Viatris Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - Η πιρφενιδόνη - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - Ανοσοκατασταλτικά - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Dapagliflozin Viatris Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - Φάρμακα που χρησιμοποιούνται στον διαβήτη - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 και 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - κλοπιδογρέλη besilate - peripheral vascular diseases; stroke; myocardial infarction - Αντιθρομβωτικοί παράγοντες - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Υψόμετρο τμήμα του st οξύ έμφραγμα του μυοκαρδίου, σε συνδυασμό με ΑΣΟ σε ιατρικά ασθενών επιλέξιμων για θρομβολυτική θεραπεία. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. Για περαιτέρω πληροφορίες ανατρέξτε στην παράγραφο 5.

PIPERACILLIN + TAZOBACTAM/VIATRIS (4G/0.5G)/VIAL POWDER FOR SOLUTION FOR INJECTION/INFUSION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

piperacillin + tazobactam/viatris (4g/0.5g)/vial powder for solution for injection/infusion

viatris limited (0000011780) damastown industrial park, mulhuddart, dublin 15 - piperacillin sodium; tazobactam sodium - powder for solution for injection/infusion - (4g/0.5g)/vial - piperacillin sodium (0059703843) 4g base; tazobactam sodium (8000001383) 500mg base - piperacillin and enzyme inhibitor

PIPERACILLIN + TAZOBACTAM/VIATRIS (2G/0.25G)/VIAL POWDER FOR SOLUTION FOR INJECTION/INFUSION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

piperacillin + tazobactam/viatris (2g/0.25g)/vial powder for solution for injection/infusion

viatris limited (0000011780) damastown industrial park, mulhuddart, dublin 15 - piperacillin sodium; tazobactam sodium - powder for solution for injection/infusion - (2g/0.25g)/vial - piperacillin sodium (0059703843) 2g base; tazobactam sodium (8000001383) 250mg base - piperacillin and enzyme inhibitor

VIASTROL 1MG/TAB ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

viastrol 1mg/tab επικαλυμμενο με λεπτο υμενιο δισκιο

ΒΙΑΝΕΞ Α.Ε. ΑΝΩΝΥΜΟΣ ΕΜΠΟΡΟΒΙΟΜΗΧΑΝΙΚΗ-ΤΟΥΡΙΣΤΙΚΗ-ΞΕΝΟΔΟΧΕΙΑΚΗ ΚΑΙ ΝΑΥΤΙΛΙΑΚΗ ΑΝΩΝΥΜΟΣ ΕΤΑΙΡΕΙΑ Δ.Τ. ΒΙΑΝΕΞ Α.Ε. - anastrozole - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 1mg/tab - 0120511731 - anastrozole - 1.000000 mg - anastrozole

BAYTRIL 10% ORAL SOLUTION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

baytril 10% oral solution

bayer animal health gmbh (0000007180) d-51368 leverkusen, germany, leverkusen, d-51368 - enrofloxacin - oral solution - 10% - enrofloxacin (0093106606) 10g - enrofloxacin